SG11201805136TA - Group b adenovirus encoding an anti-tcr-complex antibody or fragment - Google Patents

Group b adenovirus encoding an anti-tcr-complex antibody or fragment

Info

Publication number
SG11201805136TA
SG11201805136TA SG11201805136TA SG11201805136TA SG11201805136TA SG 11201805136T A SG11201805136T A SG 11201805136TA SG 11201805136T A SG11201805136T A SG 11201805136TA SG 11201805136T A SG11201805136T A SG 11201805136TA SG 11201805136T A SG11201805136T A SG 11201805136TA
Authority
SG
Singapore
Prior art keywords
international
group
fragment
tcr
antibody
Prior art date
Application number
SG11201805136TA
Inventor
Brian Robert Champion
Alice Claire Noel Bromley
Original Assignee
Psioxus Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1522334.0A external-priority patent/GB201522334D0/en
Priority claimed from GBGB1607463.5A external-priority patent/GB201607463D0/en
Priority claimed from GBGB1617206.6A external-priority patent/GB201617206D0/en
Priority claimed from GBGB1617207.4A external-priority patent/GB201617207D0/en
Application filed by Psioxus Therapeutics Ltd filed Critical Psioxus Therapeutics Ltd
Publication of SG11201805136TA publication Critical patent/SG11201805136TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 11111111011110111010101111101011111011101011111001011111101101111101111011111 International Bureau .. .... ..Yejd (10) International Publication Number (43) International Publication Date ..... ...r .....1 WO 2017/103290 Al 22 June 2017(22.06.2017) WIPO I PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 35/761 (2015.01) C07K 16/28 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 35/768 (2015.01) A61P 35/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (21) International Application Number: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP2016/081817 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (22) International Filing Date: KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, 19 December 2016 (19.12.2016) MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (25) Filing Language: English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (26) Publication Language: English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 1522334.0 17 December 2015 (17.12.2015) GB (84) Designated States (unless otherwise indicated, for every 1607463.5 29 April 2016 (29.04.2016) GB kind of regional protection available): ARIPO (BW, GH, 1617207.4 10 October 2016 (10.10.2016) GB GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 1617206.6 10 October 2016 (10.10.2016) GB TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant: PSIOXUS THERAPEUTICS LIMITED DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, [GB/GB]; 154B Milton Park, Abingdon Oxfordshire OX14 LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, 4SD (GB). SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, (72) Inventors: CHAMPION, Brian Robert; 154B Brook GW, KM, ML, MR, NE, SN, TD, TG). Drive, Milton Park, Hertfordshire, Abingdon Oxfordshire Published: OX14 4SD (GB). BROWN, Alice Claire Noel; 154B with international search report (Art. 21(3)) Oxfordshire OX14 Brook Drive, Milton Park, Abingdon 4SD (GB). — with sequence listing of description (Rule 5.2(a)) part — (74) Agents: STERLING IP et al.; Orion House, Bessemer Road, Welwyn Garden City Hertfordshire AL7 1HH (GB). 1-1 © tz\ ei M © ,-1 (54) Title: GROUP B ADENOVIRUS ENCODING AN ANTI-TCR-COMPLEX ANTIBODY OR FRAGMENT 1-1 C (57) : The present disclosure relates to a replication deficient oncolytic viral vector or replication capable group B oncolytic N adenovirus selected from the group consisting of Adl 1 and enadenotucirev, wherein the virus encodes an antibody or a binding frag - O ment thereof for expression on the surface of a cancer cell, wherein said antibody or binding fragment is specific to a CD3 protein of a T-cell receptor complex (TCR), wherein the virus does not encode a B7 protein or an active fragment thereof, pharmaceutical com- positions comprising the same, and use of any one of the same in treatment, particularly in the treatment of cancer.
SG11201805136TA 2015-12-17 2016-12-19 Group b adenovirus encoding an anti-tcr-complex antibody or fragment SG11201805136TA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1522334.0A GB201522334D0 (en) 2015-12-17 2015-12-17 Method
GBGB1607463.5A GB201607463D0 (en) 2016-04-29 2016-04-29 Method
GBGB1617206.6A GB201617206D0 (en) 2016-10-10 2016-10-10 Method
GBGB1617207.4A GB201617207D0 (en) 2016-10-10 2016-10-10 Method
PCT/EP2016/081817 WO2017103290A1 (en) 2015-12-17 2016-12-19 Group b adenovirus encoding an anti-tcr-complex antibody or fragment

Publications (1)

Publication Number Publication Date
SG11201805136TA true SG11201805136TA (en) 2018-07-30

Family

ID=57794239

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201805137XA SG11201805137XA (en) 2015-12-17 2016-12-19 Virus encoding an anti-tcr-complex antibody or fragment
SG11201805136TA SG11201805136TA (en) 2015-12-17 2016-12-19 Group b adenovirus encoding an anti-tcr-complex antibody or fragment

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201805137XA SG11201805137XA (en) 2015-12-17 2016-12-19 Virus encoding an anti-tcr-complex antibody or fragment

Country Status (19)

Country Link
US (1) US11155622B2 (en)
EP (2) EP3389682B1 (en)
JP (2) JP7064437B2 (en)
KR (2) KR20180108590A (en)
CN (2) CN108697745A (en)
AU (2) AU2016372576A1 (en)
BR (2) BR112018012179A2 (en)
CA (1) CA3006859A1 (en)
CL (1) CL2018001611A1 (en)
CO (1) CO2018005945A2 (en)
DK (1) DK3389682T3 (en)
EA (2) EA201891021A1 (en)
IL (2) IL260027B (en)
MX (1) MX2018007249A (en)
MY (1) MY193281A (en)
PH (1) PH12018501291A1 (en)
SG (2) SG11201805137XA (en)
WO (2) WO2017103290A1 (en)
ZA (1) ZA201803523B (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2927968C (en) 2013-10-25 2023-02-21 Psioxus Therapeutics Limited Oncolytic adenoviruses armed with heterologous genes
EP3261669B1 (en) 2015-02-25 2022-08-03 Memorial Sloan Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
KR20180006916A (en) 2015-04-17 2018-01-19 메모리얼 슬로안-케터링 캔서 센터 Use of MVA or MVA delta E3L as an immunotherapeutic agent for solid tumors
PT3288573T (en) 2015-04-30 2020-03-25 Psioxus Therapeutics Ltd Oncolytic adenovirus encoding a b7 protein
TW201722985A (en) 2015-11-02 2017-07-01 戊瑞治療有限公司 CD80 extracellular domain polypeptides and their use in cancer treatment
AU2016372576A1 (en) 2015-12-17 2018-06-21 Psioxus Therapeutics Limited Virus encoding an anti-TCR-complex antibody or fragment
AU2017222687B2 (en) 2016-02-25 2022-02-24 Memorial Sloan Kettering Cancer Center Recombinant MVA or MVADELE3L expressing human Flt3L and use thereof as immuno-therapeutic agents against solid tumors
CN116440176A (en) 2016-02-25 2023-07-18 纪念斯隆凯特琳癌症中心 Replication-competent attenuated vaccinia virus with thymidine kinase deficiency and with or without human FLT3L or GM-CSF expression
WO2022047417A1 (en) * 2020-08-31 2022-03-03 Exuma Biotech Corp. Anti-idiotype compositions and methods of use thereof
RU2758007C2 (en) * 2016-06-30 2021-10-25 Онкорус, Инк. Delivery of therapeutic polypeptides via pseudotyped oncolytic viruses
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
WO2018083259A1 (en) * 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
WO2018083258A1 (en) * 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding at least three transgenes
WO2018083257A1 (en) * 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
WO2018201014A1 (en) 2017-04-28 2018-11-01 Five Prime Therapeutics, Inc. Methods of treatment with cd80 extracellular domain polypeptides
US11242509B2 (en) 2017-05-12 2022-02-08 Memorial Sloan Kettering Cancer Center Vaccinia virus mutants useful for cancer immunotherapy
SG11202000691XA (en) * 2017-07-26 2020-02-27 Oncorus Inc Oncolytic viral vectors and uses thereof
WO2019133847A1 (en) 2017-12-29 2019-07-04 Oncorus, Inc. Oncolytic viral delivery of therapeutic polypeptides
US20210040167A1 (en) * 2018-03-05 2021-02-11 The Schepens Eye Research Institute, Inc. Engineered vegf variants for retinal neuroprotection, promotion of axon growth and axon regeneration
CA3095427A1 (en) * 2018-03-30 2019-10-03 Tomoki Todo Swelling-suppressive oncolytic virus
AU2019292580A1 (en) * 2018-06-29 2021-02-04 Krystal Biotech, Inc. Compositions and methods for antibody delivery
WO2020050630A1 (en) 2018-09-07 2020-03-12 주식회사 케이티 Method and device for performing wireless communication in unlicensed band
CN110393808B (en) * 2019-01-07 2022-06-03 四川安可康生物医药有限公司 Immune oncolytic virus combined medicine for enhancing systemic immune response and application thereof
US20200215133A1 (en) * 2019-01-07 2020-07-09 Sichuan Oncocare Biopharmaceutical, Inc. Combination of immuno-oncolytic virus drugs for enhancing systemic immune response and application thereof
KR102503349B1 (en) 2019-05-14 2023-02-23 프로벤션 바이오, 인코포레이티드 Methods and compositions for preventing type 1 diabetes
JP7337373B2 (en) * 2019-07-29 2023-09-04 サイアス株式会社 Method for producing antigen-specific T cells
CN110551222B (en) * 2019-08-27 2023-06-06 重庆市畜牧科学院 Novel bifunctional antibody and application thereof
US20230027475A1 (en) * 2019-09-13 2023-01-26 adMare Therapeutics Society Anti-oncolytic virus antigen antibodies and methods of using same
CN114729305A (en) * 2019-10-17 2022-07-08 苏州丹罗医药有限公司 Chimeric antigen receptor for immunotherapy, preparation method and application thereof
WO2022170219A1 (en) 2021-02-05 2022-08-11 Iovance Biotherapeutics, Inc. Adjuvant therapy for cancer
CN113355296A (en) * 2021-06-07 2021-09-07 中国人民解放军空军军医大学 Recombinant oncolytic newcastle disease virus expressing human CCL19 and application thereof
WO2023118670A1 (en) 2021-12-23 2023-06-29 Helsingin Yliopisto Method for screening a signal peptide for efficient expression and secretion of a heterologous polypeptide in mammalian cells
CN114891126B (en) * 2022-06-23 2023-05-09 上海安库生医生物科技有限公司 Double-binding protein targeting FSHR and CD3 molecules and application thereof

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5358866A (en) 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
US5801029A (en) 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
FR2705361B1 (en) 1993-05-18 1995-08-04 Centre Nat Rech Scient Viral vectors and use in gene therapy.
NZ269156A (en) 1993-07-13 1996-03-26 Rhone Poulenc Rorer Sa Defective recombinant adenovirus vector incapable of replicating autonomously in a target cell and its use in gene therapy
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5830686A (en) 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
US5677170A (en) 1994-03-02 1997-10-14 The Johns Hopkins University In vitro transposition of artificial transposons
US5877011A (en) 1996-11-20 1999-03-02 Genzyme Corporation Chimeric adenoviral vectors
CN1242051A (en) 1996-12-31 2000-01-19 昂尼克斯药物公司 Cytopathic viruses for therapy and prophylaxis of neoplasia
US6420524B1 (en) 1997-02-20 2002-07-16 Johns Hopkins University School Of Medicine Gain of function mutations in ATP-dependent transposition proteins
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US6291214B1 (en) 1998-05-11 2001-09-18 Glaxo Wellcome Inc. System for generating recombinant viruses
US20020019051A1 (en) 1998-05-27 2002-02-14 Monika Lusky Chimeric adenoviral vectors
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
CN1110553C (en) 1998-07-15 2003-06-04 杭州赛狮生物技术开发有限公司 Gene engineering adenovirus and its application
WO2000015823A1 (en) 1998-09-11 2000-03-23 Genvec, Inc. Alternatively targeted adenovirus
CA2678259C (en) 1998-12-09 2016-10-18 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services A recombinant vector expressing multiple costimulatory molecules and uses thereof
DE60014489T3 (en) 1999-05-17 2010-08-12 Crucell Holland B.V. Adenovirus-derived gene transfer vehicles containing at least one type adenovirus type 35 element
AU5464000A (en) 1999-06-01 2000-12-18 University Of Washington Recombinant adenoviral vectors for cell specific infection and genome integration and expressing chimeric fiber proteins
US7396679B2 (en) 1999-11-15 2008-07-08 Onyx Pharmaceuticals, Inc. Oncolytic adenovirus
DE60107203T3 (en) 2000-01-21 2009-07-23 Biovex Ltd. HERPES VIRUSES FOR GENE THERAPY
US7456009B2 (en) 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
WO2001092549A2 (en) 2000-05-31 2001-12-06 Genvec, Inc. Method and composition for targeting an adenoviral vector
DE60234496D1 (en) 2001-01-04 2010-01-07 Goeran Wadell VIRUS VECTOR FOR GENE THERAPY
US20050175589A1 (en) 2001-07-13 2005-08-11 Btg International Limited Anti-neoplastic viral agents
AR039067A1 (en) 2001-11-09 2005-02-09 Pfizer Prod Inc ANTIBODIES FOR CD40
EP1327688A1 (en) 2002-01-14 2003-07-16 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Adenoviruses with enhanced lytic potency
JP2005515784A (en) 2002-02-01 2005-06-02 トランジェーヌ、ソシエテ、アノニム Adenoviral vector for modulating cellular activity associated with POD
US20060147420A1 (en) 2004-03-10 2006-07-06 Juan Fueyo Oncolytic adenovirus armed with therapeutic genes
AU2003223775A1 (en) 2002-04-30 2003-11-17 Duke University Adeno-associated viral vectors and methods for their production from hybrid adenovirus and for their use
US20040167088A1 (en) 2003-02-25 2004-08-26 Genvec, Inc. Method of using adenoviral vectors with increased persistence in vivo
WO2004087930A1 (en) 2003-03-28 2004-10-14 Saint Louis University Adenovirus replication-competent vectors expressing trail
US20050136035A1 (en) * 2003-06-03 2005-06-23 Derek Ko Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
JP2007530004A (en) 2003-07-18 2007-11-01 オニックス ファーマシューティカルズ，インコーポレイティド Subgroup B adenoviral vectors for treating diseases
KR101229731B1 (en) 2003-10-16 2013-03-07 암젠 리서치 (뮌헨) 게엠베하 Multispecific deimmunized cd3-binders
US20080292592A1 (en) 2004-04-30 2008-11-27 Sunil Chada Oncolytic Adenovirus Armed with Therapeutic Genes
CA2836987C (en) 2004-05-26 2016-07-05 Psioxus Therapeutics Limited Chimeric adenoviruses for use in cancer treatment
US20060292682A1 (en) 2004-07-22 2006-12-28 Hawkins Lynda K Addition of transgenes into adenoviral vectors
WO2006039045A2 (en) 2004-09-01 2006-04-13 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenoviral vectors able to transduce apcs, potential use in immune response generation
US7550296B2 (en) 2004-12-01 2009-06-23 Bayer Schering Pharma Ag Generation of replication competent viruses for therapeutic use
EP1929021A2 (en) 2005-08-31 2008-06-11 Genvec, Inc. Adenoviral vector-based malaria vaccines
DE102005055128B4 (en) 2005-11-15 2015-04-02 Universität Rostock Viral vector, its use for the treatment of hepatocellular carcinoma and pharmaceutical agents comprising the vector
ES2304281B1 (en) 2006-02-01 2009-08-12 Dnatrix Inc. ADENOVIRUS ONCOLITICOS FOR THE TREATMENT OF CANCER.
JP2008050051A (en) 2006-08-28 2008-03-06 Bokuson Uesuto:Kk Dispensing head
CA2673520A1 (en) 2006-12-22 2008-07-03 Bayer Schering Pharma Aktiengesellschaft Generation of oncolytic adenoviruses and uses thereof
TW200951143A (en) 2008-05-27 2009-12-16 Oncolytics Biotech Inc Modulating interstitial pressure and oncolytic viral delivery and distribution
CN101381742A (en) 2008-10-23 2009-03-11 浙江理工大学 Late promoter targeting regulation oncolytic adenovirus pCN305 vector and construction method and application thereof
EP2486137B1 (en) 2009-10-05 2018-05-30 Ya-Fang Mei Replication-competent ad11p based viral vectors
CN107090440B (en) 2010-08-16 2021-10-22 萨克生物研究学院 Adenovirus assembly method
CA2812093A1 (en) 2010-09-24 2012-03-29 Oncos Therapeutics Oy Oncolytic adenoviral vectors coding for monoclonal anti - ctla - 4 antibodies
WO2013074507A2 (en) 2011-11-14 2013-05-23 Regenerative Sciences, Llc Suspended particle delivery systems and methods
CN102586327B (en) 2012-01-18 2013-09-11 陕西师范大学 D24 fiber protein modified conditionally replicating adenovirus carrier with exogenous gene by one-step method and application of carrier
WO2014138314A1 (en) * 2013-03-05 2014-09-12 Baylor College Of Medicine Oncolytic virus
GB201322851D0 (en) 2013-12-23 2014-02-12 Psioxus Therapeutics Ltd Method
GB201318793D0 (en) * 2013-10-24 2013-12-11 Plaquetec Ltd Vascular Biomarkers
CA2927968C (en) * 2013-10-25 2023-02-21 Psioxus Therapeutics Limited Oncolytic adenoviruses armed with heterologous genes
EP3653714A1 (en) 2013-11-22 2020-05-20 DNAtrix, Inc. Adenovirus expressing immune cell stimulatory receptor agonist(s)
SG11201608194VA (en) * 2014-04-03 2016-10-28 Igm Biosciences Inc Modified j-chain
GB201406608D0 (en) * 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
EP3186366A2 (en) 2014-08-27 2017-07-05 Psioxus Therapeutics Limited A process for the production of adenovirus
GB201503500D0 (en) * 2015-03-02 2015-04-15 Ucl Business Plc Cell
CN107406859A (en) 2015-03-17 2017-11-28 倾斜生物医疗公司 The oncolytic adenovirus of encoding bispecific antibody and relative method and purposes
PT3288573T (en) 2015-04-30 2020-03-25 Psioxus Therapeutics Ltd Oncolytic adenovirus encoding a b7 protein
AU2016372576A1 (en) 2015-12-17 2018-06-21 Psioxus Therapeutics Limited Virus encoding an anti-TCR-complex antibody or fragment
AU2017233072B2 (en) 2016-03-18 2020-12-24 Nantcell, Inc. Multimodal vector for dendritic cell infection
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
SG11201901716TA (en) 2016-08-29 2019-03-28 Psioxus Therapeutics Ltd Adenovirus armed with bispecific t cell engager (bite)
AU2017345764A1 (en) 2016-10-20 2019-05-02 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
WO2018083257A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
WO2018083258A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding at least three transgenes
WO2018083259A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
GB201801614D0 (en) 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation

Also Published As

Publication number Publication date
AU2016369485A1 (en) 2018-06-21
EP3389683A1 (en) 2018-10-24
DK3389682T3 (en) 2022-01-24
MX2018007249A (en) 2019-05-16
EP3389683B8 (en) 2023-05-03
CN108697745A (en) 2018-10-23
CL2018001611A1 (en) 2018-09-14
EP3389682B1 (en) 2021-11-17
IL260027A (en) 2018-07-31
EA201891022A1 (en) 2019-01-31
MY193281A (en) 2022-09-30
EP3389682A1 (en) 2018-10-24
WO2017103290A1 (en) 2017-06-22
CN108697746A (en) 2018-10-23
AU2016372576A1 (en) 2018-06-21
BR112018012180A2 (en) 2018-12-04
US20190077865A1 (en) 2019-03-14
PH12018501291A1 (en) 2019-02-18
AU2016369485B2 (en) 2024-02-01
ZA201803523B (en) 2022-07-27
BR112018012179A2 (en) 2018-12-04
KR20180108590A (en) 2018-10-04
IL260033A (en) 2018-07-31
JP7064437B2 (en) 2022-05-10
JP2019502379A (en) 2019-01-31
CA3006859A1 (en) 2017-06-22
IL260027B (en) 2022-07-01
SG11201805137XA (en) 2018-07-30
EP3389683B1 (en) 2023-03-29
EA201891021A1 (en) 2018-11-30
JP2019508017A (en) 2019-03-28
CO2018005945A2 (en) 2018-08-21
US11155622B2 (en) 2021-10-26
US20180369304A1 (en) 2018-12-27
WO2017103291A1 (en) 2017-06-22
KR20180107105A (en) 2018-10-01

Similar Documents

Publication Publication Date Title
SG11201805136TA (en) Group b adenovirus encoding an anti-tcr-complex antibody or fragment
SG11201901716TA (en) Adenovirus armed with bispecific t cell engager (bite)
SG11201808125RA (en) Methods for solid tumor treatment
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201903407XA (en) Secretable variant immunomodulatory proteins and engineered cell therapy
SG11201807187XA (en) Binding members to pd-l1
SG11201906223TA (en) Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer
SG11201900561XA (en) Chemokine receptor modulators and uses thereof
SG11201805451TA (en) Immune effector cell therapies with enhanced efficacy
SG11201804190YA (en) Method and system for blockchain variant using digital signatures
SG11201805888SA (en) Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
SG11201805253SA (en) Compositions and methods related to multimodal therapeutic cell systems for cancer indications
SG11201900480YA (en) Anti-tim-3 antibodies
SG11201806322QA (en) Maytansinoid derivatives, conjugates thereof, and methods of use
SG11201907427YA (en) Engineered transferrin receptor binding polypeptides
SG11201900635QA (en) Chimeric antigen receptors targeting bcma and methods of use thereof
SG11201808457PA (en) Icos ligand variant immunomodulatory proteins and uses thereof
SG11201908578YA (en) Fc-optimized anti-cd25 for tumour specific cell depletion
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201900200XA (en) Tgfb antibodies, methods, and uses
SG11201909561RA (en) Octree-based convolutional neural network
SG11201908238SA (en) Anti-c5 antibodies and uses thereof
SG11201804185VA (en) Features on a porous membrane
SG11201900085TA (en) Modified ligand-gated ion channels and methods of use
SG11201805204WA (en) Nicotine particle capsule